View source for Kenneth Hillan

[[File:kennethhillann.jpg|200px|thumb|left|Kenneth Hillan]]

==Country==

United States

==Birth - Death==


==Occupation==

Business, Medicine

==Description==

Former Chief Therapeutics Officer, 23andMe (consumer genetics and research company) from 2019 to 2023.  President of Research & Development at Archaogen (2011-2018).  Served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in China. 

==Further Reading/Research==

* https://www.linkedin.com/in/kenneth-hillan-713b5526/
* https://www.sangamo.com/board-of-directors/kenneth-hillan/
* https://theorg.com/org/23andme/org-chart/kenneth-hillan-m-b-c-h-b

<html><br />
<a href="#" 
  onclick="
    window.open(
      'https://www.facebook.com/sharer/sharer.php?u='+encodeURIComponent(location.href), 
      'facebook-share-dialog', 
      'width=626,height=436'); 
    return false;">
  Share on Facebook
</a></html>

<html><br />
<a class="twitter-share-button"
  href="https://twitter.com/intent/tweet">
Tweet</a></html